CHANGCHUN BCHT BIOTECHNOLOGY CO revenue breakdown overview

CHANGCHUN BCHT BIOTECHNOLOGY CO revenue for the last year amounted to 1.82 B CNY, the most of which — 882.50 M CNY — came from its highest performing source at the moment, Shingles Vaccine. The greatest contribution to the revenue figure was made by China — last year it brought CHANGCHUN BCHT BIOTECHNOLOGY CO 1.79 B CNY, and the year before that — 1.05 B CNY.